Basolateral P2X4-like receptors regulate the extracellular ATP-stimulated epithelial Na+ channel activity in renal epithelia.
Extracellular ATP initiates potent effects on sodium transport across renal epithelia through membrane-associated purinergic receptors. Dependent on the location of these receptors, ATP either inhibits or stimulates sodium reabsorption. Using A6 cells, transepithelial electrical resistance measurements, and scanning ion conductance microscopy, we have identified the purinergic receptors involved in the stimulatory action on the epithelial cell basolateral plasma membrane. Addition of the potent P2X(4) receptor agonist 2-methylthio-ATP (2MeSATP) to the basolateral side of the A6 monolayer stimulated amiloride-sensitive sodium conductance and produced similar cell morphological changes to those found with ATPgammaS, aldosterone, or hypotonic stress. The agonist potency order determined by sodium conductance changes of the monolayer was: 2MeSATP >or= ATPgammaS > CTP, a similar agonist potency profile to that of cloned P2X(4) receptors but with higher sensitivity for beta, gamma-methylene-ATP and alpha,beta-methylene-ATP. We further demonstrated that the ATP effect on sodium transport was potentiated by ivermectin, not blocked by suramin and PPADS, enhanced by Zn(2+) but not by Cu(2+), and significantly reduced but not totally inhibited by brilliant blue G. These results led us to conclude that basolateral P2X(4)-like receptors were involved. We suggest that there is a reciprocal purinergic system acting both at a basolateral and apical location for control of Na(+) transport. This requires a mechanism within the cell that leads to either basolateral or apical ATP release to regulate renal tubular function.
Zhang
Yanjun
Y
Division of Medicine, Imperial College London, London, UK.
Sanchez
Daniel
D
Gorelik
Julia
J
Klenerman
David
D
Lab
Max
M
Edwards
Christopher
C
Korchev
Yuri
Y
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D000450:Aldosterone / Q000502:physiology; D000584:Amiloride / Q000494:pharmacology; D000818:Animals; D003570:Cytidine Triphosphate / Q000494:pharmacology; D004232:Diuretics / Q000494:pharmacology; D017097:Electric Impedance; D004848:Epithelium / Q000187:drug effects / Q000378:metabolism; D007559:Ivermectin / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D020527:Microscopy, Scanning Probe; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2 / Q000502:physiology*; D058848:Receptors, Purinergic P2X4; D015222:Sodium Channels / Q000187:drug effects / Q000378:metabolism*; D013873:Thionucleotides / Q000378:metabolism; D014982:Xenopus laevis
D004232:Diuretics; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D058848:Receptors, Purinergic P2X4; D015222:Sodium Channels; D013873:Thionucleotides; C022571:adenosine 5'-O-(3-thiotriphosphate); D000450:Aldosterone; D003570:Cytidine Triphosphate; D007559:Ivermectin; D000584:Amiloride; D000255:Adenosine Triphosphate; C008501:2-methylthio-ATP